Last year saw record-breaking tallies, and dealmaking this year has been unexpectedly resilient: At $12.9 billion across 461 deals per PitchBook, 2022 so far is not on pace to match last year’s record dealmaking numbers, but it compares favorably to previous years.
Digitalization is imperative: Life sciences executives are
renovating their tech stacks and implementing the latest tools
to achieve efficiencies, cost reductions, and innovation.
Current market conditions are not insurmountable but may
require more complex strategies: Fundraising efforts are still
succeeding for some of the bestprepared enterprises, and even
though liquidity is largely on hold due to the slowdown, life sciences
companies are forging ahead with an eye on longer-term outcomes.
